Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 November 2015Next earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Sat, 23 Nov 2024 00:41:06 GMTDividend
Analysts recommendations
Institutional Ownership
VYGR Latest News
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences:
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET.
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in multiple upcoming investor conferences:
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.51 per share a year ago.
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024, at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024, at 7:00 a.m. ET.
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc.
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotech company focused on advancing neurogenetic medicines, announced today that the initial participants have received doses in a Phase 1a trial of VY-TAU01, an experimental anti-tau antibody designed to block the spread of pathological tau in Alzheimer's disease.
Voyager Therapeutics (VYGR) reported a quarterly loss of $0.20 per share, beating the Zacks Consensus Estimate of a loss of $0.44. This is a decrease from earnings of $2.94 per share in the same quarter last year.
The company's strength lies in its TRACER capsids technology that can deliver therapeutic molecules to the brain, leading to multimillion-dollar deals with pharmaceutical giants, such as Novartis. Despite the risks and uncertainties, long-term investors may be rewarded once the company's products reach clinical trial validation. Voyager's investors should expect share price volatility. Nonetheless, based on my financial valuation and the potential upsides, I consider this company as a “buy”.
- 1(current)
What type of business is Voyager Therapeutics?
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
What sector is Voyager Therapeutics in?
Voyager Therapeutics is in the Healthcare sector
What industry is Voyager Therapeutics in?
Voyager Therapeutics is in the Biotechnology industry
What country is Voyager Therapeutics from?
Voyager Therapeutics is headquartered in United States
When did Voyager Therapeutics go public?
Voyager Therapeutics initial public offering (IPO) was on 11 November 2015
What is Voyager Therapeutics website?
https://www.voyagertherapeutics.com
Is Voyager Therapeutics in the S&P 500?
No, Voyager Therapeutics is not included in the S&P 500 index
Is Voyager Therapeutics in the NASDAQ 100?
No, Voyager Therapeutics is not included in the NASDAQ 100 index
Is Voyager Therapeutics in the Dow Jones?
No, Voyager Therapeutics is not included in the Dow Jones index
When was Voyager Therapeutics the previous earnings report?
No data
When does Voyager Therapeutics earnings report?
The next expected earnings date for Voyager Therapeutics is 28 February 2025